Prelude Capital Management, LLC Tyme Technologies, Inc. Transaction History

Prelude Capital Management, LLC

$1.39 Billion
Q2 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.35 $6,422 - $9,773	27,924 Added 176.31%	43,762 $12,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $4,434 - $10,769	15,838 New	15,838 $6,000
Q4 2019 Feb 14, 2020	SELL	$1.0 - $1.49 $578 - $861	-578 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$0.97 - $1.77 $137 - $251	-142 Reduced 19.72%	578 $1,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $155 - $306	-162 Reduced 18.37%	720 $1,000
Q1 2019 May 15, 2019	SELL	$1.76 - $3.73 $140,685 - $298,157	-79,935 Reduced 98.91%	882 $2,000
Q4 2018 Feb 14, 2019	BUY	$2.01 - $4.21 $158,225 - $331,406	78,719 Added 3752.1%	80,817 $298,000
Q3 2018 Nov 14, 2018	SELL	$2.18 - $3.44 $488 - $770	-224 Reduced 9.65%	2,098 $6,000
Q2 2018 Aug 14, 2018	SELL	$2.05 - $4.09 $3,769 - $7,521	-1,839 Reduced 44.2%	2,322 $7,000
Q1 2018 May 15, 2018	BUY	$2.12 - $7.0 $8,821 - $29,127	4,161 New	4,161 $9,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.